LA JOLLA, Calif., Sept. 3, 2020 /PRNewswire/ -- Regulus
Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company
focused on the discovery and development of innovative medicines
targeting microRNAs ("Regulus"), today announced that Jay Hagan, President and Chief Executive Officer
of Regulus, will present at the Wells Fargo Virtual Healthcare
Conference on Wednesday, September 9,
2020 at 10:40 AM EDT.
A live webcast of the presentation will be available through the
investor relations section of the Company's website at
www.regulusrx.com.
About Regulus
Regulus Therapeutics Inc. (Nasdaq: RGLS) is a biopharmaceutical
company focused on the discovery and development of innovative
medicines targeting microRNAs. Regulus has leveraged its
oligonucleotide drug discovery and development expertise to develop
a pipeline complemented by a rich intellectual property estate in
the microRNA field. Regulus maintains its corporate
headquarters in La Jolla,
CA.
Forward-Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995, including statements associated with the completion of
preclinical and clinical activities concerning the RGLS4326
program, the sufficiency of the data resulting from the ongoing or
planned preclinical studies required to recommence clinical studies
for extended duration dosing and the timing of preclinical and
clinical activities. Because such statements are subject to
risks and uncertainties, actual results may differ materially from
those expressed or implied by such forward-looking statements.
Words such as "believes," "anticipates," "plans," "expects,"
"intends," "will," "goal," "potential" and similar expressions are
intended to identify forward-looking statements. These
forward-looking statements are based upon Regulus' current
expectations and involve assumptions that may never materialize or
may prove to be incorrect. Actual results and the timing of
events could differ materially from those anticipated in such
forward-looking statements as a result of various risks and
uncertainties, which include, without limitation, risks associated
with the process of discovering, developing and commercializing
drugs that are safe and effective for use as human therapeutics and
in the endeavor of building a business around such drugs, and
feedback from the FDA. In addition, while Regulus expects the
COVID-19 pandemic to adversely affect its business operations and
financial results, the extent of the impact on Regulus' ability to
achieve its preclinical and clinical development objectives and the
value of and market for its common stock, will depend on future
developments that are highly uncertain and cannot be predicted with
confidence at this time, such as the ultimate duration of the
pandemic, travel restrictions, quarantines, social distancing and
business closure requirements in the U.S. and in other countries,
and the effectiveness of actions taken globally to contain and
treat the disease. These and other risks are described
in additional detail in Regulus' filings with the Securities and
Exchange Commission. All forward-looking statements contained
in this press release speak only as of the date on which they were
made. Regulus undertakes no obligation to update such statements to
reflect events that occur or circumstances that exist after the
date on which they were made.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/regulus-therapeutics-to-present-at-the-2020-wells-fargo-virtual-healthcare-conference-301123689.html
SOURCE Regulus Therapeutics Inc.